没食子儿茶素没食子酸酯诱导结直肠癌的免疫原性细胞死亡并增强癌症免疫治疗。
Epigallocatechin-3-gallate induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer.
机构信息
Department of Laboratory Medicine, Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, China; State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China.
School of Medicine, Wuhan University of Science and Technology, Wuhan, China.
出版信息
Biochem Biophys Res Commun. 2024 Dec 3;736:150907. doi: 10.1016/j.bbrc.2024.150907. Epub 2024 Oct 25.
The induction of immunogenic cell death (ICD) can activate antitumor immune response to potentiate cancer immunotherapy. In this study, we observed the antitumor activity following combinatorial therapy with anti-CTLA4 antibody and epigallocatechin-3-gallate (EGCG) in CT26 tumors.Indeed, EGCG triggered colon cancer cells ICD with the secretion of high-mobility group protein B1 (HMGB1) and the surface expression of calreticulin (CRT) and heat shock protein 70 (HSP70). Mice treated with EGCG promoted the maturation of dendritic cells and enhanced the effector function of CD8 T cells within tumors to remodel the tumor immune microenvironment. Overall, these results indicate that EGCG, a novel ICD inducer, triggers ICD in CRC, and provides a new concept for cancer immunotherapy.
免疫原性细胞死亡（ICD）的诱导可以激活抗肿瘤免疫反应，从而增强癌症免疫治疗。在这项研究中，我们观察了抗 CTLA4 抗体和表没食子儿茶素没食子酸酯（EGCG）联合治疗 CT26 肿瘤后的抗肿瘤活性。事实上，EGCG 通过高迁移率族蛋白 B1（HMGB1）的分泌和钙网蛋白（CRT）和热休克蛋白 70（HSP70）的表面表达引发结肠癌细胞 ICD。用 EGCG 处理的小鼠促进树突状细胞的成熟，并增强肿瘤内 CD8 T 细胞的效应功能，重塑肿瘤免疫微环境。总的来说，这些结果表明，EGCG 作为一种新型的 ICD 诱导剂，可引发 CRC 中的 ICD，并为癌症免疫治疗提供了新的概念。
Zotero 插件